ГоловнаArchive of numbers2015Volume 23, issue 3(84)Efficiency of natalizumab (tysabri) in patients with multiple sclerosis
Title of the article Efficiency of natalizumab (tysabri) in patients with multiple sclerosis
Authors Vasylovskyi Vitalii
Voloshyna Natalia
Negreba Tetiana
Pisotska Kseniia
In the section DIAGNOSTICS AND THERAPY OF NEUROLOGICAL DISORDERS
Year 2015 Issue Volume 23, issue 3(84) Pages 29-35
Type of article Scientific article Index UDK 616.832-004.2-08:001.8 Index BBK -
Abstract The article is concerned with the efficacy, safety and tolerability of Natalizumab in 30 patients with recurrent and secondary-progressive course of multiple sclerosis. In the work there was carried out the analysis of clinical and radiological fi ndings in patients with recurrent (RC) and secondary progressive course (SPC) of multiple sclerosis (MS) treated with Natalizumab (Tysabri). Evaluation of the clinical and radiological activity of disease, based on the results of treatment, was performed immediately after the course of treatment with Natalizumab and 1 year after its completion. The dynamics of clinical relapses and their average frequency, progression of disability according to the data of EDSS scale, the number of gadolinium enhancing lesions was taking into account. On the basis of those indicators there have been developed the criteria for high, moderate and low eff ectiveness of treatment. It was proved the clinical and radiological efficacy of Natalizumab as a second-line agent in JC-negative patients, modifying the aggressive course of MS. The signifi cant reduction in annual relapses rate at RC and exacerbations in relapsing course of SPC, the reduction in the average disability score on EDSS scale and slowing of progression rate in both types of courses, a signifi cant reduction of the risk of transition of RC into SPC, transformation of recurrent variant of secondary progression into more favorable progressive course of SPC, reducing of the number of active gadolinium-enhancing lesions on MRI, prevailing at RC, persistent afterimpression of therapeutic eff ect of treatment during one year of the follow-up observations expand therapeutic opportunities of Natalizumab and allow us to recommend the drug not only in RC, but also in SPC.
Key words multiple sclerosis, Natalizumab (Tysabri), effi cacy of treatment, clinical and radiological activity of the disease
Access to full text version of the article pdf download
Bibliography 1. Clinical effects of natalizumab multiple sclerosis appear early in treatment course, regardless of baseline disease activity [Text] / L. Kappos, R. Rudick, C. Polman et al. // Journal of Neurology. — 2010. — Vol. 257. — Suppl. 1. — S22—S23. 2. Шмидт, Т. Е. Натализумаб в лечении ремиттирующего рассеянного склероза [Текст] / Т. Е. Шмидт // Международный неврологический журнал. — 2014. — № 3. — С. 57—61. 3. Alternatives to current disesase-modifying treatment in MS: what do we need and what can we expect in the future? [Text] / L. Карpos, J. Kuhle, A. Gass et al. // J. Neurol. — 2004; 251 (Suppl. 5): V/57—V/64. 4. Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis — new aspects and practical application [Text] // J. Neurol. — 2004 Nov; 251(11): 1329—39. 5. Alfa4-integrin antagonism with natalizumab [Text] / O. Stüve, R. Gold, A. Chan, et al. // J. Neurol. — 2008. — Vol. 255, Suppl. 6. — P. 58—65. 6. Immune surveillance in multiple sclerosis patents treated with natalizumab // O. Stüve, C. M. Marra, K. R. Serome et al. // Ann. Neurol. — 2006. — Vol. 59. — P. 743—747. 7. The efficacy of natalizumab in patents with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL [Text] / M. Hutchinson, L. Kappos, P. Calabresi et al. // J. Neurol. — 2009. — Vol. 256. — P. 405—415. 8. А randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis [Text] / C. H. Polman, P. O’Connor, E. Harvdova, et al. // N. Engl. J. Med. — 2006. Vol. 554. — P. 899—910. 9. Long-term safety and impact of natalizumab on disease activity and disability progression in patients with relapsing-remitting MS in clinical practice: TYSABRI® Observational Program (TOP) [Text] / Н. Wiendl, L. Kappos, M. Trojano et al. In: Conference Proceedings "14th Congress of European-Federation-of-Neurological-Societies" // European Journal of Neurology. — 2010. — Vol. 257, Suppl. 1. — S. 22, 078. 10. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. [Text] / L. Prosperini, C. Gianni, L. Leonardi et al. // Multiple Scleros. — 2012; 18(1): 64—71. 11. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. [Text] / F. Rinaldi, M. Calabrese, D. Seppi et al. // Ibid. — 2012; 18: 1760—7. 12. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results [Text] / H. Butzkueven, L. Kappos, F. Pelegrini et al. // J. Neurol. Neurosurg. Psychiatry. — 2014 Feb 14. doi:10.1136/jnnp-2013-306936. 13. Clinical predictors of an optimal response to natalizumab in multiple sclerosis. [Text] / J. Sargento-Freitas, S. Batista, C. Macario et al. // J. Clin. Neurosci. — 2013; 20: 659—62. 14. Randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis [Text] / C. H. Polman, P. W. O’Connor, E. Harvdova et al. // N. Engl. J. Med. — 2006; 354 (9): 899—910. 15. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study [Text] / E. Harvdova, S. Galetta, M. Hutchinson et al. // Lancet Neurol. — 2009; 8(3): 254—60. 16. Lublin, F. D. Effect of relapses on development of residual deficit in multiple sclerosis [Text] / F. D. Lublin, V. Barier, G. Cutter // Neurology. — 2003. — Vol. 61. — P. 1528—1532. 17. По материалам ХIХ конгресса Европейской федерации неврологических обществ (EFNS). Обозрение. Часть 1 // Невро- ло гический журнал. — 2010. — № 2. — С. 59—64. 18. Johnson, K. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis [Text] / K. Johnson, // Neurologist. — 2007. — Vol. 13. — P. 182—187. 19. Multiple sclerosis patients, benefit-risks versus treatment efficacy [Text] / K. Johnson, G. Houtven, S. Ozdemir et al. // J. Neurol. — 2009. — Vol. 256. — P. 554— 562. 20. Hammarin, A. L. Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy [Text] / A. L. Hammarin, G. Bogdanovic, V. Svedhem et al. // J. Clin. Microbiol. — 1996. — Vol. 34. — P. 2929—2932. 21. Asymptomatic reactivation of JC virus in patients treated with natalizumab [Text] / Y. Chen, E. Bord, T. Tompkins et al. // N. Engl. J. Med. — 2009. — Vol. 361. — P. 1067—1074. 22. Шмидт, Т. Е. Лечение и дифференциальный диагноз рас сеянного склероза и оптикомиелита (по материалам 29-го конгресса ECTRIMS) [Текст] / Т. Е. Шмидт // Неврологический журнал. — 2014. — Т. 19. — № 2. — С. 53—62. 23. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” [Text] / C. H. Polman, S. C. Reingold, G. Edan et al. // Ann. Neurol. — 2005; 58: 840—6. 24. Негреба Т. В. Течение и прогноз современных форм рас- сеянного склероза» // Свідоцтво про реєстрацію авторського права на твір № 30251 від 15.09.2009. 25. Волошина Н. П., Негреба Т. В., Левченко І. Л., Ткачова Т. М., Єгоркіна О. В. Прогностичні критерії при різних типах пере- бігу розсіяного склерозу // Авторське право на науковий твір № 39160 від 14.07.2011 р. 26. Рассеянный склероз в Украине: распространенность, тече- ние, прогноз, лечение, фармакоэкономика [Текст] / Н. П. Волошина, В. И. Тайцлин, Т. В. Негреба и др. // Український вісник психо- неврології. — 2007. — Т. 15, вип. 1(50). — С. 6—21.